News
DePoly gets a Economic Award
DePoly gets the Swiss Economic Award 2025 in the “Deeptech / Life Science” category, with a CHF 25’000 cash prize. The award ceremony took place this Friday in Interlaken, attended by part of the Sion-based startup team and representatives from the political and economic spheres. DePoly’s innovative technology breaks down PET and polyester into…
Read MoreSwitzerland Invests CHF 666 Million to Join European Research Programmes
Fantastic news for the Swiss Health Valley and the Swiss scientific community! On 4 June 2025, the Swiss Parliament approved an additional CHF 666 million to support Switzerland’s full participation in key European research and innovation programmes — including Horizon Europe, Euratom, and Digital Europe. Switzerland must be able to participate in European…
Read MoreBrainQuant SA Revolutionizes Neurodegenerative Diseases Detection
BrainQuant SA is a Wyss Center Geneva spin-off co-founded in partnership with EPFL, University of Geneva (UNIGE), and HCK Healthcare Konnect. The new company, led by internationally recognized experts in neuroradiology, bioengineering, and digital health, is poised to transform how neurodegenerative diseases are detected. BrainQuant harnesses the power of artificial intelligence to analyze Arterial…
Read MoreUNIGE 3R Prize 2025 Awarded for Breakthrough in Kidney Cancer Research
Since 2016, the University of Geneva (UNIGE) has awarded the 3R Prize to recognize research that advances the replacement, reduction, or refinement (3R) of animal use in science. The 2025 prize was awarded on 3 June 2025 to Prof. Patrycja Nowak-Sliwinska and Dr. Daniel Benamran for developing a novel protocol to culture kidney cancer organoids…
Read MoreClaire Charmet is the New CEO of CHUV
The new CEO of CHUV took up her position on 1 June 2025. Claire Charmet is already familiar with the institution, having observed it in her role as a member of the strategic council. She has made hospital management her career for the past 15 years. Aged 42, Claire Charmet has been managing the…
Read More11 Swiss Life Sciences projects selected by MassChallenge
MassChallenge Switzerland, part of the global MassChallenge network, announced the 103 early-stage startups selected for the 2025 accelerator programme. 11 Swiss Life Sciences projects are in the list. Healthtech Actival (Switzerland): Actival has a patented approach of directly manufacturing clear dental aligners with integrated microfluidic channels. These microfluidic channels act as reservoirs that slowly release beneficial antibacterial…
Read MoreSwiss Health Valley Startups Shine at Major Pitching Events
The Swiss Health Valley continues to be a powerhouse of innovation, as multiple startups made their mark at major pitching events across Europe. These groundbreaking companies are not only transforming health and wellness but also bringing international recognition to the region. At Start Contest 2024-2025, PMAX Labs emerged as the grand prize winner…
Read MoreSyrhatech Completes A CHF 4.5 Million Financing Round
Syrhatech, a French-Swiss CDMO innovating in the development and manufacture of injectable medical devices based in particular on hyaluronic acid, announces the closing of an investment of CHF 4.5 million, completed with strategic investors. Funding for innovation and industrial capacity This investment will enable Syrhatech to strengthen its R&D team at its site in Geneva, and to deploy a…
Read MoreNewBiologix Licences Xcell-Eng-HEK293 Cell Line to Recipharm
NewBiologix, a Biopôle-based (Vaud)Swiss biotech innovator, has granted a non-exclusive licence to Recipharm Advanced Bio. The agreement gives Recipharm access to NewBiologix’s Xcell-Eng-HEK293 cell lines, enabling the efficient production of recombinant Adeno-Associated Viruses (rAAVs) for cell and gene therapies. The licensed cell lines offer high-yield, GMP-ready viral production, accelerating the path to clinical trials.…
Read MoreHedera Dx Secures €15 Million Series A
Hedera Dx Raises €15M Series A to Expand Access to Precision Oncology Across Europe Hedera Dx, a Vaud-Based techbio company advancing precision cancer care, announced the successful close of a €15 million Series A financing round. The round was led by Vsquared Ventures, with new investor Tesi joining and strong support from existing backers…
Read More